Ocular Therapeutix, Inc. (OCUL)

NASDAQ: OCUL · IEX Real-Time Price · USD
5.14
-0.15 (-2.84%)
Mar 30, 2023, 12:56 PM EDT - Market open
-2.84%
Market Cap 397.62M
Revenue (ttm) 51.49M
Net Income (ttm) -71.04M
Shares Out 77.51M
EPS (ttm) -0.97
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 366,192
Open 5.35
Previous Close 5.29
Day's Range 5.12 - 5.40
52-Week Range 2.57 - 6.53
Beta 1.27
Analysts Buy
Price Target 12.09 (+135.21%)
Earnings Date May 8, 2023

About OCUL

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing ... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jul 25, 2014
Employees 228
Stock Exchange NASDAQ
Ticker Symbol OCUL
Full Company Profile

Financial Performance

In 2022, OCUL's revenue was $51.49 million, an increase of 18.32% compared to the previous year's $43.52 million. Losses were -$71.04 million, 984.1% more than in 2021.

Financial Statements

Analyst Forecast

According to 13 analysts, the average rating for OCUL stock is "Buy." The 12-month stock price forecast is $12.09, which is an increase of 135.21% from the latest price.

Price Target
$12.09
(135.21% upside)
Analyst Consensus: Buy
Stock Forecasts

News

What Makes Ocular Therapeutix (OCUL) a Good Fit for 'Trend Investing'

Ocular Therapeutix (OCUL) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed thr...

3 weeks ago - Zacks Investment Research

Ocular Therapeutix (OCUL) Reports Q4 Loss, Tops Revenue Estimates

Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of 4% and 3.50%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

3 weeks ago - Zacks Investment Research

Ocular Therapeutix™ Provides Fourth Quarter and Year-End 2022 Results and Corporate Update

Presented Positive 10-month Interim Data from the U.S.-based Phase 1 Clinical Trial of OTX-TKI (axitinib intravitreal implant) for the Treatment of Wet AMD at the Angiogenesis, Exudation, and Degenera...

3 weeks ago - GlobeNewsWire

Ocular Therapeutix (OCUL) Moves 35.1% Higher: Will This Strength Last?

Ocular Therapeutix (OCUL) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price i...

1 month ago - Zacks Investment Research

Ocular Therapeutix™ Announces Interim 10-month Data from the Ongoing U.S. Phase 1 Clinical Trial Evaluating OTX-TKI for the Treatment of Wet AMD

All OTX-TKI treated subjects who were rescue-free at the Month 7 interim analysis remained rescue-free, extending the 73% rescue-free rate up to Month 10

1 month ago - GlobeNewsWire

Ocular Therapeutix™ Provides 2022 Year End Corporate Update and Reviews Expected 2023 Milestones

Dextenza® Net Product Revenue in the Fourth Quarter of 2022 is Estimated to be $13.6 million, Growing Approximately 14% Over Previous Quarter and Approximately 11% Over Same Quarter of Prior Year

2 months ago - GlobeNewsWire

Ocular Therapeutix (OCUL) Reports Q3 Loss, Lags Revenue Estimates (Revised)

Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of -30.43% and 18.63%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock...

5 months ago - Zacks Investment Research

Ocular Therapeutix (OCUL) Reports Q3 Loss, Lags Revenue Estimates

Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of -34.78% and 18.63%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock...

5 months ago - Zacks Investment Research

Ocular Therapeutix™ Reports Third Quarter 2022 Financial Results and Business Update

BEDFORD, Mass--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therap...

5 months ago - Business Wire

Ocular Therapeutix (OCUL) Soars 24.2%: Is Further Upside Left in the Stock?

Ocular Therapeutix (OCUL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the nea...

6 months ago - Zacks Investment Research

Ocular (OCUL) Announces Positive Data on Wet AMD Candidate

Ocular (OCUL) interim seven-month data on OTX-TKI from a phase I study for treating wet age-related macular degeneration (wet AMD) shows a favorable safety profile, and stable and sustained visual acu...

6 months ago - Zacks Investment Research

Ocular Therapeutix™ Announces Interim 7-month Data from U.S. Phase 1 Clinical Trial of OTX-TKI for the Treatment of Wet AMD

BEDFORD, Mass--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therap...

6 months ago - Business Wire

Ocular Therapeutix™ To Present Data at the American Academy of Ophthalmology (AAO) 2022 Annual Meeting

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative thera...

6 months ago - Business Wire

Ocular Therapeutix™ to Present at the H.C. Wainwright 24th Annual Global Investment Conference

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative thera...

7 months ago - Business Wire

Ocular Therapeutix™ to Present at the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative thera...

8 months ago - Business Wire

Ocular Therapeutix (OCUL) Reports Q2 Loss, Lags Revenue Estimates

Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of -21.74% and 11.18%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

8 months ago - Zacks Investment Research

Ocular Therapeutix™ Reports Second Quarter 2022 Financial Results and Business Update

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative thera...

8 months ago - Business Wire

Ocular Therapeutix™ To Report Second Quarter 2022 Financial Results

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative thera...

8 months ago - Business Wire

Aurion Biotech Appoints Dr. Michael Goldstein as President and Chief Medical Officer

SEATTLE, BOSTON & TOKYO--(BUSINESS WIRE)--Aurion Biotech, whose mission is to restore vision to millions of patients with its life-changing regenerative therapies, today announced it has appointed Mic...

10 months ago - Business Wire

Ocular Therapeutix™ Announces Organizational Changes to Support Development for Retinal Diseases

BEDFORD, Mass.--(BUSINESS WIRE)--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases...

10 months ago - Business Wire

Ocular Therapeutix™ to Present at the Jefferies Healthcare Conference

BEDFORD, Mass.--(BUSINESS WIRE)--Ocular Therapeutix, Inc. (Nasdaq: OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases...

10 months ago - Business Wire

Ocular Therapeutix (OCUL) Reports Q1 Loss, Lags Revenue Estimates

Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of 12% and 12.26%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

11 months ago - Zacks Investment Research

Ocular Therapeutix™ Reports First Quarter 2022 Financial Results and Business Update

BEDFORD, Mass.--(BUSINESS WIRE)--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases...

11 months ago - Business Wire